Long-term effects of topical corticosteroids in the nose

1992 ◽  
Vol 106 (9) ◽  
pp. 810-812 ◽  
Author(s):  
M. Bende ◽  
J. Mark

AbstractIn a prospective study, biopsies were taken from the septal mucosa in 21 patients of whom 11 had been using topical nasal corticosteroids. In contrast to the effect of long-term treatment with corticosteroids in the skin, but in accordance with previous investigations of the nasal mucosa, no histopathological changes of significance were found, although the biopsies were taken from different sites. These findings do not suggest that topically corticosteroids are harmful to the nasal mucosa.

2018 ◽  
Vol 33 (6) ◽  
pp. e2676 ◽  
Author(s):  
Laura Musetti ◽  
Antonio Tundo ◽  
Alessandra Benedetti ◽  
Gabriele Massimetti ◽  
Erika Cambiali ◽  
...  

2018 ◽  
Vol 84 ◽  
pp. 62-67 ◽  
Author(s):  
Andrzej Cechnicki ◽  
Anna Bielańska ◽  
Dagmara Mętel ◽  
Katarzyna Susz ◽  
Piotr Błądziński ◽  
...  

2021 ◽  
pp. 27-28
Author(s):  
Kalishankar Das ◽  
Sneha Bhowmick ◽  
Athokpam Poireiton

PURPOSE: The study aims to evaluate the safety of topical corticosteroids Loteprednol and Flurometholone in treating VKC keeping in mind the efcacy of the drugs. METHOD: A prospective study was done including 200 eyes of 107 patients with severe VKC (grade 3,4). 7 patients were lost during follow up. Patients were selected randomly. 100 eyes of 50 patients were treated with Flurometholone 1% and another 100 eyes of 50 patients with Loteprednol 0.5%. All patients were followed up over a period of 3 months. The study duration is 18 months. RESULT: The normal IOP ranging between 10-21 mm Hg. Out of 100 eyes receiving urometholone in the study period of 18 months, 3 eyes (3%) showed IOP ≥ 30mm Hg and 5 eyes (5%) showed IOP between 21-30mm Hg. Out of the rest 100 eyes receiving Loteprednol, 3 eyes (3%) showed IOP between 21-30 mm Hg while none (0%) reached an IOP over 30 mm Hg. CONCLUSION: Loteprednol is more effective than Flurometholone and it consistently demonstrated a low propensity to elevate IOP, regardless of formulation, dosage regimen both during short term as well as long term treatment of VKC patient.


2018 ◽  
Vol 238 ◽  
pp. 213-217 ◽  
Author(s):  
Maximilian Pilhatsch ◽  
Anne Berghöfer ◽  
René Mayer-Pelinski ◽  
Gunnar Berghöfer ◽  
Roland Ricken ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document